Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

August 14, 2026 - 21:40

Citius Pharmaceuticals, Inc. has released its financial results for the fiscal third quarter ending June 30, 2026, alongside an update on its operations. The company, which focuses on developing first-in-class products for critical care settings, also shared news about its majority-owned subsidiary, Citius Oncology, Inc.

The quarterly report covers the three-month period that closed on June 30. Management used the announcement to outline recent milestones and the current state of its pipeline. A significant portion of the update centered on the work being done at Citius Oncology, which is publicly traded under its own ticker.

The company's leadership emphasized continued execution on its strategic goals, particularly in advancing its late-stage product candidates. While specific financial figures were included in the report, the broader message pointed to steady progress across its development programs.

Citius Pharma remains focused on bringing new treatment options to hospital and specialty care environments. The business update portion of the release touched on both operational achievements and the financial position of the company as it moves through the remainder of the fiscal year.

Investors and industry watchers were given a look at where the company stands midway through its fiscal calendar. The update arrives as the biopharmaceutical sector continues to see heightened activity around specialty care and oncology assets.